Jay Kranzler Net Worth

Jay Kranzler biography

Dr. Jay D. Kranzler M.D., Ph.D. serves as Independent Director of the Company since February 2017. Dr. Kranzler has been a Founder, Chief Executive Officer (“CEO”), Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Executive Chairman of Perception Neuroscience, a company that he cofounded, a regenerative medicine company, and is a Board Member of Pastorus and ImmunoBrain Checkpoint, all companies focused on developing therapeutics for psychiatric or neurological disorders. Dr. Kranzler started his career at McKinsey & Company where he helped establish the Firm’s pharmaceutical practice. He served as CEO of Cytel Corporation, a company focused on the development of immunomodulatory drugs. Following Cytel, Dr. Kranzler became the CEO of Cypress Bioscience, where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia. Dr. Kranzler was also Vice President, Head of Worldwide External R&D Innovation and Strategic Investments at Pfizer. During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics, and is the inventor on over 30 patents. Dr. Kranzler graduated from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology. Kranzler is qualified to serve on our Board due to his management experience, his service as an executive of biopharmaceutical companies and his knowledge of our business and industry.

What is the salary of Jay Kranzler?

As the Independent Director of Avenue Therapeutics Inc, the total compensation of Jay Kranzler at Avenue Therapeutics Inc is $50,000. There are 5 executives at Avenue Therapeutics Inc getting paid more, with Lucy Lu having the highest compensation of $639,783.

How old is Jay Kranzler?

Jay Kranzler is 61, he's been the Independent Director of Avenue Therapeutics Inc since 2017. There are 5 older and 6 younger executives at Avenue Therapeutics Inc. The oldest executive at Avenue Therapeutics Inc is Dr. Scott A. Reines M.D., Ph.D., 74, who is the Interim Chief Medical Officer.

What's Jay Kranzler's mailing address?

Jay's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.

Insiders trading at Avenue Therapeutics Inc

Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss и Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.

What does Avenue Therapeutics Inc do?

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Avenue Therapeutics Inc executives and stock owners

Avenue Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lucy Lu,
  President, Chief Executive Officer, Director
• Dr. Xiaoqin Lu M.D.,
  Pres, CEO & Director
• Joseph Vazzano,
  Chief Financial Officer, Principal Financial Officer and Corporate Secretary
• Joseph Walter Vazzano,
  CFO, Principal Financial Officer & Company Sec.
• Neil Herskowitz,
  Independent Director
• Jay Kranzler,
  Independent Director
• Thomas Moore,
  Independent Director
• Dr. Lindsay Allan Rosenwald,
  Exec. Chairman
• Garrett Ingram,
  Director
• Jaideep Gogtay,
  Director
• Lindsay Rosenwald,
  Executive Chairman of the Board
• Dr. Scott A. Reines M.D., Ph.D.,
  Interim Chief Medical Officer
• Jeffrey Paley,
  Director
• Akhtar Samad,
  Director
• Scott Reines,
  Interim Chief Medical Officer
• Michael S Weiss,
  Director
• Curtis Gale Oltmans,
  Director
• Pharmaceuticals, Inc. Inva Gen,
  10% owner
• Robert L Davidow,
  10% owner
• Biotech, Inc. Fortress,
  10% owner
• David Jin,
  Interim PFO and COO
• Faith L. Charles,
  Director